Unicycive Historical Financial Ratios

UNCY Stock

USD 4.93 0.32 6.94%

Unicycive Therapeutics is promptly reporting on over 80 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Price To Sales Ratio of 16.04, Dividend Yield of 0.0016, PTB Ratio of 75.15 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Unicycive Therapeutics financial condition quickly.

Quick Ratio Current Ratio

Build AI portfolio with Unicycive Stock

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Unicycive Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.

About Unicycive Financial Ratios Analysis

Unicycive TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Unicycive Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Unicycive financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Unicycive Therapeutics history.

Unicycive Therapeutics Financial Ratios Chart

At this time, Unicycive Therapeutics' PTB Ratio is fairly stable compared to the past year. PB Ratio is likely to rise to 75.15 in 2025, whereas Book Value Per Share is likely to drop 0.11 in 2025.

Price To Sales Ratio Dividend Yield Ev To Sales Payables Turnover

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Unicycive Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Unicycive Therapeutics sales, a figure that is much harder to manipulate than other Unicycive Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Dividend Yield

Dividend Yield is Unicycive Therapeutics dividend as a percentage of Unicycive Therapeutics stock price. Unicycive Therapeutics dividend yield is a measure of Unicycive Therapeutics stock productivity, which can be interpreted as interest rate earned on an Unicycive Therapeutics investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Most ratios from Unicycive Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Unicycive Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Unicycive Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.At this time, Unicycive Therapeutics' PTB Ratio is fairly stable compared to the past year. PB Ratio is likely to rise to 75.15 in 2025, whereas Book Value Per Share is likely to drop 0.11 in 2025.

	2010	2024	2025 (projected)
Dividend Yield	0.002059	0.001853	0.001647
Price To Sales Ratio	8.55	28.4	16.04

Dividend Yield Price To Sales Ratio

Unicycive Therapeutics fundamentals Correlations

	Price To Sales Ratio	Dividend Yield	Ptb Ratio	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Net Income Per Share	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Payout Ratio	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio	Return On Tangible Assets
Price To Sales Ratio		-0.42	0.65	-0.03	-0.19	-0.25	-0.75	0.65	1.0	-0.25	-0.05	-0.34	0.92	0.92	0.04	0.58	-0.06	0.62	0.66	0.58	-0.91	-0.07	-0.09	0.58	0.54	0.45
Dividend Yield	-0.42		-0.9	-0.07	-0.11	-0.22	0.59	-0.9	-0.36	-0.22	0.1	-0.24	-0.72	-0.72	0.13	-0.32	0.1	-0.79	-0.34	-0.32	0.74	0.24	0.29	-0.33	-0.27	-0.37
Ptb Ratio	0.65	-0.9		0.29	-0.05	0.01	-0.73	1.0	0.6	0.01	-0.03	0.0	0.83	0.82	0.07	0.57	-0.19	0.89	0.5	0.57	-0.85	-0.09	-0.2	0.58	0.5	0.61
Book Value Per Share	-0.03	-0.07	0.29		-0.05	-0.2	0.0	0.29	-0.04	-0.2	0.04	-0.29	0.0	-0.01	0.61	0.53	-0.02	0.07	-0.02	0.53	0.0	-0.28	-0.06	0.55	0.53	0.33
Free Cash Flow Yield	-0.19	-0.11	-0.05	-0.05		0.96	0.64	-0.05	-0.21	0.96	-0.86	0.87	-0.14	-0.13	-0.02	-0.69	0.92	0.11	-0.83	-0.69	0.12	-0.46	-0.95	-0.67	-0.68	-0.34
Operating Cash Flow Per Share	-0.25	-0.22	0.01	-0.2	0.96		0.57	0.01	-0.27	1.0	-0.77	0.97	-0.15	-0.14	-0.18	-0.75	0.78	0.22	-0.78	-0.75	0.12	-0.29	-0.87	-0.73	-0.75	-0.34
Capex To Depreciation	-0.75	0.59	-0.73	0.0	0.64	0.57		-0.73	-0.73	0.57	-0.46	0.54	-0.82	-0.82	0.07	-0.8	0.64	-0.6	-0.95	-0.8	0.82	-0.17	-0.41	-0.79	-0.75	-0.56
Pb Ratio	0.65	-0.9	1.0	0.29	-0.05	0.01	-0.73		0.6	0.01	-0.03	0.0	0.83	0.82	0.07	0.57	-0.19	0.89	0.5	0.57	-0.85	-0.09	-0.2	0.58	0.5	0.61
Ev To Sales	1.0	-0.36	0.6	-0.04	-0.21	-0.27	-0.73	0.6		-0.27	-0.04	-0.37	0.89	0.89	0.05	0.58	-0.05	0.58	0.66	0.58	-0.89	-0.05	-0.07	0.57	0.54	0.43
Free Cash Flow Per Share	-0.25	-0.22	0.01	-0.2	0.96	1.0	0.57	0.01	-0.27		-0.77	0.97	-0.15	-0.14	-0.18	-0.75	0.78	0.22	-0.78	-0.75	0.12	-0.29	-0.87	-0.73	-0.75	-0.35
Roic	-0.05	0.1	-0.03	0.04	-0.86	-0.77	-0.46	-0.03	-0.04	-0.77		-0.62	-0.06	-0.07	-0.35	0.5	-0.89	-0.1	0.62	0.5	0.07	0.57	0.89	0.49	0.46	0.09
Net Income Per Share	-0.34	-0.24	0.0	-0.29	0.87	0.97	0.54	0.0	-0.37	0.97	-0.62		-0.22	-0.21	-0.3	-0.79	0.61	0.25	-0.74	-0.79	0.18	-0.11	-0.74	-0.77	-0.8	-0.34
Payables Turnover	0.92	-0.72	0.83	0.0	-0.14	-0.15	-0.82	0.83	0.89	-0.15	-0.06	-0.22		1.0	-0.01	0.59	-0.09	0.72	0.66	0.59	-1.0	-0.22	-0.16	0.59	0.54	0.49
Capex To Revenue	0.92	-0.72	0.82	-0.01	-0.13	-0.14	-0.82	0.82	0.89	-0.14	-0.07	-0.21	1.0		-0.01	0.59	-0.08	0.71	0.66	0.59	-1.0	-0.23	-0.16	0.59	0.54	0.49
Cash Per Share	0.04	0.13	0.07	0.61	-0.02	-0.18	0.07	0.07	0.05	-0.18	-0.35	-0.3	-0.01	-0.01		0.3	0.12	-0.13	-0.04	0.3	0.02	-0.35	-0.07	0.31	0.37	0.4
Pocfratio	0.58	-0.32	0.57	0.53	-0.69	-0.75	-0.8	0.57	0.58	-0.75	0.5	-0.79	0.59	0.59	0.3		-0.59	0.33	0.82	1.0	-0.58	-0.05	0.45	1.0	0.99	0.5
Interest Coverage	-0.06	0.1	-0.19	-0.02	0.92	0.78	0.64	-0.19	-0.05	0.78	-0.89	0.61	-0.09	-0.08	0.12	-0.59		-0.09	-0.76	-0.59	0.08	-0.59	-0.91	-0.57	-0.57	-0.32
Payout Ratio	0.62	-0.79	0.89	0.07	0.11	0.22	-0.6	0.89	0.58	0.22	-0.1	0.25	0.72	0.71	-0.13	0.33	-0.09		0.35	0.33	-0.75	0.1	-0.29	0.34	0.27	0.37
Capex To Operating Cash Flow	0.66	-0.34	0.5	-0.02	-0.83	-0.78	-0.95	0.5	0.66	-0.78	0.62	-0.74	0.66	0.66	-0.04	0.82	-0.76	0.35		0.82	-0.65	0.27	0.63	0.81	0.78	0.52
Pfcf Ratio	0.58	-0.32	0.57	0.53	-0.69	-0.75	-0.8	0.57	0.58	-0.75	0.5	-0.79	0.59	0.59	0.3	1.0	-0.59	0.33	0.82		-0.58	-0.05	0.45	1.0	0.99	0.5
Days Payables Outstanding	-0.91	0.74	-0.85	0.0	0.12	0.12	0.82	-0.85	-0.89	0.12	0.07	0.18	-1.0	-1.0	0.02	-0.58	0.08	-0.75	-0.65	-0.58		0.21	0.18	-0.58	-0.53	-0.49
Income Quality	-0.07	0.24	-0.09	-0.28	-0.46	-0.29	-0.17	-0.09	-0.05	-0.29	0.57	-0.11	-0.22	-0.23	-0.35	-0.05	-0.59	0.1	0.27	-0.05	0.21		0.56	-0.06	-0.11	0.24
Roe	-0.09	0.29	-0.2	-0.06	-0.95	-0.87	-0.41	-0.2	-0.07	-0.87	0.89	-0.74	-0.16	-0.16	-0.07	0.45	-0.91	-0.29	0.63	0.45	0.18	0.56		0.43	0.46	0.13
Ev To Operating Cash Flow	0.58	-0.33	0.58	0.55	-0.67	-0.73	-0.79	0.58	0.57	-0.73	0.49	-0.77	0.59	0.59	0.31	1.0	-0.57	0.34	0.81	1.0	-0.58	-0.06	0.43		0.99	0.5
Pe Ratio	0.54	-0.27	0.5	0.53	-0.68	-0.75	-0.75	0.5	0.54	-0.75	0.46	-0.8	0.54	0.54	0.37	0.99	-0.57	0.27	0.78	0.99	-0.53	-0.11	0.46	0.99		0.42
Return On Tangible Assets	0.45	-0.37	0.61	0.33	-0.34	-0.34	-0.56	0.61	0.43	-0.35	0.09	-0.34	0.49	0.49	0.4	0.5	-0.32	0.37	0.52	0.5	-0.49	0.24	0.13	0.5	0.42

Click cells to compare fundamentals

Unicycive Therapeutics Account Relationship Matchups

Unicycive Therapeutics fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Ptb Ratio	(28.54)	1.87	(17.45)	(5.59)	71.57	75.15
Book Value Per Share	(1.05)	(1.75)	10.99	(0.31)	(1.55)	0.11
Free Cash Flow Yield	(0.0191)	(0.19)	(1.93)	(0.86)	(0.0539)	(0.0566)
Operating Cash Flow Per Share	(0.96)	(3.85)	(10.39)	(7.45)	(0.43)	(0.45)
Pb Ratio	(28.54)	1.87	(17.45)	(5.59)	71.57	75.15
Free Cash Flow Per Share	(0.96)	(3.86)	(10.4)	(7.46)	(0.43)	(0.45)
Roic	(52.04)	(0.56)	115.76	6.93	(3.84)	(3.65)
Net Income Per Share	(1.64)	(7.09)	(12.0)	(12.45)	(0.55)	(0.58)
Pocfratio	(52.25)	(5.36)	(0.52)	(1.17)	(18.61)	(19.54)
Interest Coverage	(8.28)	(14.29)	(3.0K)	(253.34)	(452.35)	(474.97)
Pfcf Ratio	(52.25)	(5.33)	(0.52)	(1.16)	(18.57)	(19.49)
Income Quality	0.54	0.64	0.58	0.87	0.6	0.78
Roe	0.94	(0.64)	38.76	8.02	(4.94)	(4.7)
Ev To Operating Cash Flow	(53.97)	(2.54)	(0.5)	(0.68)	(17.73)	(18.61)
Pe Ratio	(30.4)	(2.91)	(0.45)	(0.7)	(14.48)	(15.2)
Return On Tangible Assets	(12.29)	(0.57)	(6.41)	(2.15)	(1.16)	(1.22)
Ev To Free Cash Flow	(53.97)	(2.52)	(0.5)	(0.68)	(17.68)	(18.56)
Earnings Yield	(0.0329)	(0.34)	(2.22)	(1.43)	(0.0691)	(0.0725)
Current Ratio	0.071	8.75	0.81	0.76	1.28	1.34
Tangible Book Value Per Share	(1.05)	(1.75)	10.99	(0.31)	(1.55)	0.11
Shareholders Equity Per Share	(1.05)	(1.75)	10.99	(0.31)	(1.55)	0.11
Debt To Equity	(0.94)	0.0186	(0.33)	(0.21)	0.1	0.11
Graham Net Net	(1.89)	9.55	(1.88)	(3.38)	0.0284	0.0299
Interest Debt Per Share	1.81	0.62	0.11	0.36	0.0126	0.012
Debt To Assets	12.32	0.0163	0.055	0.0571	0.0244	0.0232
Short Term Coverage Ratios	(0.58)	(38.19)	(100.97)	(1.0K)	(50.66)	(53.2)
Price Earnings Ratio	(30.4)	(2.91)	(0.45)	(0.7)	(14.48)	(15.2)
Price Book Value Ratio	(28.54)	1.87	(17.45)	(5.59)	71.57	75.15
Price Earnings To Growth Ratio	0.75	(0.008453)	(0.006522)	(0.1)	0.15	0.11
Price To Operating Cash Flows Ratio	(52.25)	(5.36)	(0.52)	(1.17)	(18.61)	(19.54)
Price To Free Cash Flows Ratio	(52.25)	(5.33)	(0.52)	(1.16)	(18.57)	(19.49)
Effective Tax Rate	(0.11)	(0.0614)	(3.32E-4)	0.0289	0.0333	0.0316

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

VALE	Vale SA ADR
EGY	Vaalco Energy
CMCSA	Comcast Corp

Additional Tools for Unicycive Stock Analysis

When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Shareholders Equity Per Share	Debt To Equity
Capex Per Share	Graham Net Net
Average Receivables	Revenue Per Share
Interest Debt Per Share	Debt To Assets
Enterprise Value Over E B I T D A	Short Term Coverage Ratios
Price Earnings Ratio	Operating Cycle
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Cash Conversion Cycle	Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding	Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio	Cash Flow Coverage Ratios
Price To Book Ratio	Fixed Asset Turnover
Capital Expenditure Coverage Ratio	Price Cash Flow Ratio
Enterprise Value Multiple	Debt Ratio
Cash Flow To Debt Ratio	Price Sales Ratio
Return On Assets	Asset Turnover
Net Profit Margin	Gross Profit Margin
Price Fair Value	Return On Equity

Unicycive Historical Financial Ratios

About Unicycive Financial Ratios Analysis

Unicycive Therapeutics Financial Ratios Chart

Price To Sales Ratio

Dividend Yield

Ev To Sales

Payables Turnover

Unicycive Therapeutics fundamentals Correlations

Unicycive Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Unicycive Therapeutics fundamentals Accounts

Also Currently Popular

Additional Tools for Unicycive Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ev To Sales	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Capex To Revenue	+ 1.0	Payables Turnover
Pfcf Ratio	+ 1.0	Pocfratio
Ev To Operating Cash Flow	+ 1.0	Pocfratio

Days Payables Outstanding	- 1.0	Capex To Revenue
Days Payables Outstanding	- 1.0	Payables Turnover
Capex To Operating Cash Flow	- 0.95	Capex To Depreciation
Roe	- 0.95	Free Cash Flow Yield
Roe	- 0.91	Interest Coverage
Days Payables Outstanding	- 0.91	Price To Sales Ratio